Clinical Trial Update: Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis [Phase 1]

View source ↗

Summary

A Phase 1 safety study of OA-235i in nonalcoholic steatohepatitis and nonalcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• OA-235i

Snippet

Sponsor: Oasis Pharmaceuticals, LLC | Conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver | Phase 1 | Status: COMPLETED